TIDMVLG
RNS Number : 6510E
Venture Life Group PLC
13 February 2018
Venture Life Group plc
("Venture Life" or the "Group")
Commercial update
UltraDEX distribution gains, new product launches, other
commercial progress
Venture Life Group plc (AIM: VLG), the international consumer
healthcare group focused on developing, manufacturing and
commercialising products for the self-care market, announces
further distribution gains and launches for its leading oral care
brand UltraDEX, together with other commercial progress.
UltraDEX
Venture Life announces the continued expansion of its UltraDEX
distribution in the UK, with the following new listings:
- The UltraDEX mouthwash will see a new listing in Day Lewis
Pharmacies during Q1 2018. Day Lewis is a significant pharmacy
chain with more than 300 outlets in the UK; this important pharmacy
chain further strengthens the Group's presence in the pharmacy
channel in the UK.
- The leading pharmacy chain Superdrug, which already sells the
UltraDEX mouthwash and spray, has agreed to list UltraDEX
toothpaste in approx. 460 stores in Q1 2018.
- Continuing the expansion into the convenience channel that
started with listings in the Moto motorway service stations in
2017, the UltraDEX mouth spray will be launched in all Roadchef
outlets across the UK in Q1 2018.
Following successful TV marketing campaigns in 2017, the
UltraDEX brand will also be back on television screens during Q1
2018, featuring on channels including Sky Atlantic, Sky Cinema and
Sky Living.
In addition to the UK distribution gains, the international
progress of the brand continues. UltraDEX has been launched with
the Group's new long term exclusive partners in Italy, France and
Scandinavia, following the signing of distribution agreements in
2017. First orders were delivered at the end of 2017 and we expect
these partners to begin to contribute important new revenues to the
brand.
New product launches
Q1 2018 will also see the launch of the Benecol liquid sachets
in Jordan, their first market, following the successful
registration with the Jordanian FDA. These sachets are a novel way
of delivering the cholesterol reducing active, plant stanol
esters.
Other commercial progress
Venture Life has signed a new exclusive long term partnering
agreement for Procto-eze Plus, its product for the treatment of
haemorrhoids with a new partner for the Romanian market. The
Procto-eze range is currently partnered in 12 countries and
growing.
The Lubatti skincare brand has continued to show growing
in-store sales in China though H2 2017, via the Group's exclusive
long term partner, Gialen, which has over 2,200 stores in mainland
China. The Group has already received orders in 2018 (as of end of
January) from this partner, which exceed the total revenues from
Gialen in 2017.
2018 has started well for the whole Group, with the current
order book ahead of the same point in 2017 and in line with
management's expectations.
Venture Life will announce its preliminary results for the year
ended 31 December 2017 on Thursday 22 March 2018.
Jerry Randall, CEO of Venture Life, commented: "I am delighted
to update the market on these important commercial gains for the
Group. The UltraDEX brand continues to develop in our hands, both
in the UK and internationally, demonstrating the strength of our
commercial platform to innovate and grow the brand, and there are
more exciting developments to come in 2018. The operational
leverage we have in the Group enables us to drive the margin from
growing revenues through to the bottom line, and this will continue
through 2018 and beyond, with meaningful capacity in our
operations. The progress on our other brands continues steadily.
The continued growth of in-store sales of our Lubatti brand in
China is very encouraging, and our forward looking order profile
shows this growth will continue as Lubatti develops into a
meaningful and valuable brand for the Group."
For further information please contact:
+44 (0) 1344
Venture Life Group PLC 742870
Jerry Randall, Chief Executive Officer
Northland Capital Partners Limited +44 (0) 20 3861
(Nominated Adviser and Joint Broker) 6625
Matthew Johnson/Edward Hutton (Corporate
Finance)
Bob Pountney (Corporate Broking)
Turner Pope Investments (TPI) Ltd +44 (0) 20 3621
(Joint Broker) 4120
Andy Thacker
Walbrook PR venturelife@walbrookpr.com
or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy +44 (0) 7980 541 994 / +44
(0) 7876 741 001
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising self-care
products globally. The Group's product range and pipeline currently
includes the UltraDEX oral care products range, food supplements
for lowering cholesterol and maintaining brain function,
dermo-cosmetics for addressing the signs of ageing, and medical
devices for improving minor aches and pains, dry eyes and itchy
skin.
The products, which typically are recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business, Biokosmes,
the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDVLLFFVLFEBBK
(END) Dow Jones Newswires
February 13, 2018 02:00 ET (07:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2023 to Apr 2024